Volume 68, Issue 9 (6 2010)
Tehran Univ Med J 2010, 68(9): 497-507 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
B L, A A. Recombinant parathormone and osteoporosis: a review article. Tehran Univ Med J 2010; 68 (9) :497-507
URL: http://tumj.tums.ac.ir/article-1-309-en.html
URL: http://tumj.tums.ac.ir/article-1-309-en.html
1- , emrc@tums.ac.ir
Abstract: (7859 Views)
Osteoporosis is a condition characterized with reduced bone density and destruction of the bone structure. The ideal treatment aims to reduce the risk of fracture while improving the density and structure of the bone. Parathormone (PTH) and its main analogue triparatide (rhPTH [1-34]) is a new class of anabolic medications which accelerates the healing process in the fractured bone through improving bone formation and therefore is used for treating severe osteoporosis. The present review article was designed to report the history, different types, anabolic and catabolic effects, complications, indications and contraindications of the hormone.
Keywords: Human recombinant parathyroid hormone, osteoporosis, parathyroid hormone, bone mass, treatment
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
